Core Insights - E Ink and MediaTek have collaborated to donate 58 Amazon Kindle Kids eReaders to the Boys and Girls Clubs of Metro Louisiana as part of the eRead for the Future initiative, aimed at promoting reading among children [1][4] - The donation is intended to support a Summer Reading program designed to combat reading skill loss during the summer months [2] - E Ink's ePaper technology is highlighted for its health benefits, being up to three times healthier for eyes compared to traditional LCD screens, thus providing a better reading experience [3] Company Initiatives - The eRead for the Future program reflects E Ink and MediaTek's commitment to enhancing educational opportunities for children through technology [4] - In 2024, E Ink engaged over 22 partners in the ePaper ecosystem, donating 1,024 color eReaders to benefit over 15,000 students, with a total donation value of nearly USD 1 million [5] - The previous year's initiative saved 777 metric tons of carbon emissions, emphasizing the environmental benefits of digital reading [5] Technology and Sustainability - E Ink's ePaper displays are designed to be low power and sustainable, with a pledge to use 100% renewable energy by 2030 and achieve net zero carbon emissions by 2040 [6] - The company has been recognized for its sustainability efforts, receiving validation from Science-Based Targets (SBTi) and being listed in the DJSI World and DJSI Emerging Indexes [6][7] - E Ink is the world's largest supplier of ePaper displays, enabling various applications across multiple industries [6][7]

Core Insights - BiomX Inc. is presenting positive topline results from its Phase 2 trial evaluating BX211 for the treatment of Diabetic Foot Osteomyelitis (DFO) at the Biomed Israel 2025 conference [1][2] - BX211 is a phage therapy targeting DFO associated with Staphylococcus aureus, a significant cause of amputation in diabetic patients [3][4] Presentation Details - The oral presentation titled "Precision Phage Therapy for Chronic Diabetic Foot Infections" will take place on May 21, 2025, from 12:15 to 2:15 pm IST at the InterContinental David Tel Aviv [2] - The session focuses on immunology and inflammation, highlighting opportunities in biopharma [2] BX211 Trial Results - The Phase 2 trial demonstrated that BX211 was safe and well-tolerated, with a statistically significant reduction in ulcer size (p = 0.046 at week 12; p = 0.052 at week 13) [3] - A separation from placebo was observed starting at week 7, with a difference greater than 40% by week 10 [3] - Statistically significant improvements were also noted in ulcer depth (p=0.048) and reduction of ulcer area expansion (p=0.017) [3] - The treatment period lasted 12 weeks, during which all patients received standard care, including systemic antibiotic therapy [3] Company Overview - BiomX is a clinical-stage company focused on developing natural and engineered phage therapies for chronic diseases with unmet medical needs [4] - The company utilizes its BOLT platform to customize phage compositions targeting specific bacterial pathogens [4]

Brings Proven Commercial Leadership, Reimbursement Expertise, and Global Market Insight to Support Next Phase of Growth Across Medical and Dental SegmentsROSELAND, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that Shanth Thiyagalingam, BMedSc, MMKTG, MBA, has joined its Board of Directors, effective May 14, 2025. Mr. Thiyagalingam brings more than 20 y ...

Bank of Åland PlcChange, Board/Executive Team/AuditorsMay 19, 2025, 17.00 EET Pasi Poikkeus appointed Deputy Head of the Finnish Mainland Business Area Pasi Poikkeus has been appointed Deputy Head of the Finnish Mainland Business Area, thereby also becoming a deputy member of the Executive Team. Poikkeus holds degrees in Master of Social Sciences (econ.) and Executive Master of Business Administration and is Head of the bank's Private Banking within the Finnish Mainland Business Area. He has been with Ban ...

HENDERSON, Nev., May 19, 2025 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA) presents projected revenue for each market with exclusive distribution agreement. NIKA has previously reported an estimated potential €7.9 billion in revenue from its distribution agreement in Nigeria1. With similar contact terms for the UAE, Ukraine, Iraq, Jordan, and Syria, NIKA will receive €1,980 per each set of ITV-1 with two sets necessary for one treatment. Although the UAE, Iraq, Jordan, and Syria have a low c ...

SINGAPORE, May 19, 2025 (GLOBE NEWSWIRE) -- INNEOVA Holdings Limited (Nasdaq: INEO, "INNEOVA Holdings" or the "Company"), a leading Singapore-based provider of high-quality Original Equipment Manufacturer ("OEM"), third-party branded, and in-house branded replacement parts for motor vehicles and non-vehicle combustion engines, today announced its financial results for the fiscal year ended December 31, 2024. Key Financial Highlights for Fiscal Year 2024 Revenue: $58.3 million, a 2.0% decrease from $59.5 mil ...

Marimekko Corporation, Managers’ transactions, 19 May 2025 at 4.30 p.m. EEST Marimekko Corporation: Managers' transactions (Vikkula) Marimekko Corporation’s Annual General Meeting held on 15 April 2025 resolved that approximately 40 percent of the annual remuneration of the members of the Board of Directors will be paid in Marimekko’s shares acquired from the market. Pursuant to the resolution, shares have been acquired as follows:__________________________________________ Person subject to the notification ...

Marimekko Corporation, Managers’ transactions, 19 May 2025 at 4.30 p.m. EESTMarimekko Corporation: Managers' transactions (Takebayashi)Marimekko Corporation’s Annual General Meeting held on 15 April 2025 resolved that approximately 40 percent of the annual remuneration of the members of the Board of Directors will be paid in Marimekko’s shares acquired from the market. Pursuant to the resolution, shares have been acquired as follows:____________________________________________ Person subject to the notifica ...

Marimekko Corporation, Managers’ transactions, 19 May 2025 at 4.30 p.m. EEST Marimekko Corporation: Managers' transactions (Kangas-Kärki) Marimekko Corporation’s Annual General Meeting held on 15 April 2025 resolved that approximately 40 percent of the annual remuneration of the members of the Board of Directors will be paid in Marimekko’s shares acquired from the market. Pursuant to the resolution, shares have been acquired as follows:____________________________________________Person subject to the notifi ...

Marimekko Corporation, Managers’ transactions, 19 May 2025 at 4.30 p.m. EESTMarimekko Corporation: Managers' transactions (Chen)Marimekko Corporation’s Annual General Meeting held on 15 April 2025 resolved that approximately 40 percent of the annual remuneration of the members of the Board of Directors will be paid in Marimekko’s shares acquired from the market. Pursuant to the resolution, shares have been acquired as follows:____________________________________________ Person subject to the notification re ...